Nanobiotix (NASDAQ:NBTX) reported quarterly losses of $(1.17) per share which beat the analyst consensus estimate of $(1.66) by 29.52 percent. This is a 32.37 percent increase over losses of $(1.73) per share from the same period last year. The company reported quarterly sales of $39.323 million which beat the analyst consensus estimate of $13.680 million by 187.45 percent. This is a 681.30 percent increase over sales of $5.033 million the same period last year.
Nanobiotix FY 2023 GAAP EPS $(1.17) Beats $(1.66) Estimate, Sales $39.323M Beat $13.680M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.